drugset / Trial / NCT02015507

An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on Ivacaftor and VX-661 in Combination With Ivacaftor

NCT02015507

Phase 1 Completed 34 enrolled Vertex Pharmaceuticals Incorporated
Non-randomizedCrossoverOpen-labelTreatment

Summary

To evaluate the effect of ciprofloxacin on the pharmacokinetics (PK) of ivacaftor and on the pharmacokinetics of VX-661 when administered in combination with ivacaftor

Timeline

Start
2014-01
Primary completion
2014-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Ciprofloxacin Small molecule
Subject Ivacaftor Other / unclassified
Subject tezacaftor Other / unclassified

Indications